VPC
OVID icon

Vestal Point Capital’s Ovid Therapeutics OVID Stock Holding History

Vestal Point Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-85,429
Closed -$275K – 68
2023
Q4 		$275K Buy
+85,429
New +$292K 0.03% 45

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vestal Point Capital's OVID Position: Q1 2024 in Review

Vestal Point Capital sold out of Ovid Therapeutics (OVID) in Q1 2024, closing a stake of 85,429 shares — an estimated $275K sold.

Vestal Point Capital first reported a position in OVID in Q4 2023 and held it in 1 quarter. The position peaked at $275K in Q4 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q1 2024.

  • Vestal Point Capital reported no remaining Ovid Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Vestal Point Capital sold 85,429 Ovid Therapeutics shares in Q1 2024, an estimated $275K.
  • Vestal Point Capital first reported a position in Ovid Therapeutics in Q4 2023 and held it in 1 quarter.
  • Vestal Point Capital's Ovid Therapeutics position peaked at $275K in Q4 2023.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2024.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.